The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Market Value Expansion Is Expected For The Leber Congenital Amaurosis Market Over The Forecast Period?
The leber congenital amaurosis market size has experienced significant growth in recent years. It is projected to expand from $1.06 billion in 2025 to $1.12 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.5%. This historical growth can be primarily attributed to factors such as limited treatment options for inherited retinal disorders, increasing awareness of rare genetic eye diseases, advancements in retinal imaging technologies, growth in pediatric ophthalmology services, and early research in gene replacement therapy.
The leber congenital amaurosis market size is projected to experience substantial expansion over the upcoming years. This market is forecast to reach $1.39 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.5%. This anticipated growth during the forecast period is attributable to several factors, including increasing investment in ophthalmic gene therapy research, the expansion of precision medicine initiatives, a rise in regulatory approvals for treatments for rare diseases, the growing uptake of advanced genetic testing, and improved healthcare access for rare genetic disorders. Key trends expected during this period encompass the broadened approval of gene therapies for inherited retinal diseases, an increased emphasis on early genetic screening and diagnosis, the proliferation of clinical trials for innovative retinal regeneration therapies, greater integration of assistive vision technologies, and significant progress in retinal prosthesis and bionic eye solutions.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22033&type=smp
Which Growth Drivers Are Expected To Support The Leber Congenital Amaurosis Market Forward?
The rising occurrence of inherited retinal disorders is projected to fuel the expansion of the leber congenital amaurosis (LCA) market. Inherited retinal diseases (IRDs) are defined as genetic conditions impacting the retina, which is the light-sensitive tissue located at the posterior of the eye and essential for sight. This rise in inherited retinal diseases can be ascribed to enhancements in genetic testing, greater awareness and diagnostic capabilities, alongside extended life expectancies. Progress in genetic testing has facilitated easier diagnosis of inherited retinal diseases, resulting in a higher number of identified cases. leber congenital amaurosis contributes to a deeper understanding of inherited retinal diseases by uncovering genetic mutations and mechanisms of the disease, which in turn aids in the creation of specific therapies and treatments. For example, data from January 2025, provided by the UK Parliament’s House of Commons Library, a UK-based government administration, indicated that around 25,000 individuals in the UK suffered from inherited retinal diseases in 2024, marking a 2% yearly increase. Consequently, the growing incidence of inherited retinal diseases is a key driver for the leber congenital amaurosis market.
How Does Segment Analysis Break Down The Leber Congenital Amaurosis Market Structure?
The leber congenital amaurosis market covered in this report is segmented –
1) By Treatment Type: Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices, Other Treatments
2) By Age Of Onset: Congenital Leber Congenital Amaurosis (LCA) (From Birth), Early Childhood Leber Congenital Amaurosis (LCA) (1-5 Years), Late-Onset Leber Congenital Amaurosis (LCA) (6 Years And Above)
3) By Distribution Channel: Direct Tender, Retail Sales
4) By End User: Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings, Other End Users
Subsegments:
1) By Gene Therapy: RPE65 Gene Replacement Therapy, CRISPR-Based Gene Editing, AAV (Adeno-Associated Virus) Vector Therapy, Emerging Experimental Gene Therapies
2) By Pharmaceutical Drugs: Retinoid-Based Therapies, Neuroprotective Agents, Anti-Inflammatory Drugs, Antioxidant Therapies
3) By Retinal Prosthesis: Implantable Retinal Chips, Artificial Retinal Stimulation Devices, Bionic Eye Technology
4) By Assistive Devices: Low Vision Aids, Screen Readers and Braille Devices, Mobility Aids for Vision Impairment
5) By Other Treatments: Stem Cell Therapy, Optogenetics-Based Treatments, Visual Rehabilitation Programs, Nutritional and Dietary Interventions
What Trends Are Influencing The Leber Congenital Amaurosis Market?
Leading firms within the leber congenital amaurosis market are prioritizing the creation of novel approaches, including RNA-based therapies, to enhance the recovery of vision and the handling of the condition. These RNA-based therapies utilize RNA molecules to address diseases by interfering with genetic mechanisms. Examples encompass mRNA vaccines, siRNA therapies, antisense oligonucleotides, and RNA aptamers. As an illustration, Laboratoires Théa S.A.S., a pharmaceutical company from France, introduced Sepul Bio in January 2025. This specialized business unit is dedicated to progressing RNA therapies for inherited retinal diseases, specifically focusing on sepofarsen for leber congenital amaurosis 10 (LCA10) and ultevursen for USH2A-associated retinitis pigmentosa. Following the successful administration of the initial patient dose in the LUNA Phase 2b clinical trial for ultevursen, Sepul Bio is well-positioned to achieve considerable advancements in tackling these uncommon genetic conditions.
Which Organizations Are Involved In The Leber Congenital Amaurosis Market?
Major companies operating in the leber congenital amaurosis market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Invitae Corporation, Novelion Therapeutics Inc., Andelyn Biosciences Inc., CD Genomics Inc., Editas Medicine Inc., MeiraGTx Holdings plc, Sangamo Therapeutics Inc., LKC Technologies Inc., Aldeyra Therapeutics Inc., Asper Biogene OÜ, Allergan Inc., ProQR Therapeutics N.V., GenSight Biologics S.A., Ocugen Inc., Ophthotech Corporation, Atsena Therapeutics Inc., HuidaGene Therapeutics Co. Ltd.
Access The Complete Leber Congenital Amaurosis Market Report:
https://www.thebusinessresearchcompany.com/report/leber-congenital-amaurosis-global-market-report
Which Region Leads The Leber Congenital Amaurosis Market By Size?
North America was the largest region in the leber congenital amaurosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leber congenital amaurosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Leber Congenital Amaurosis Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=22033&type=smp
Browse Through More Reports Similar to the Global Leber Congenital Amaurosis Market 2026, By The Business Research Company
Congenital Heart Disease Chd Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report
Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2026
Gauchers Disease Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/gauchers-disease-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model